
Tulane University awarded \$9.2 million NIH contract for innovative oral vaccine development

Keith Brannon kbrannon@tulane.edu February 01, 2024 1:00 PM



Elizabeth Norton, PhD, associate professor of microbiology and immunology at Tulane University School of Medicine, will lead the project to develop a new oral vaccine platform that could be used to prevent a variety of infectious diseases. (Photo by Cheryl Gerber)

The National Institute of Allergy and Infectious Diseases (NIAID), within the National Institutes of Health (NIH), has awarded a <u>contract</u> for up to \$9.2 million over the next five years to Tulane University to collaborate with Biotech company <u>Q-Vant</u>

<u>Biosciences Inc.</u> to develop a promising new platform for oral vaccines that could be used to prevent a variety of infectious diseases. <u>Read the full story here.</u>